Volume | 1,109,590 |
|
|||||
News | - | ||||||
Day High | 10.89 | Low High |
|||||
Day Low | 10.41 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
EyePoint Pharmaceuticals Inc | EYPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.86 | 10.41 | 10.89 | 10.71 | 10.75 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,637 | 1,109,590 | $ 10.76 | $ 11,937,408 | - | 5.67 - 30.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:19:57 | formt | 400 | $ 11.00 | USD |
EyePoint Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
533.19M | 49.83M | - | 46.02M | -70.8M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EyePoint Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EYPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.11 | 11.42 | 10.41 | 10.99 | 859,049 | -0.11 | -0.99% |
1 Month | 20.25 | 21.255 | 10.41 | 11.91 | 1,550,460 | -9.25 | -45.68% |
3 Months | 25.02 | 26.0599 | 10.41 | 16.39 | 1,141,630 | -14.02 | -56.04% |
6 Months | 6.35 | 30.99 | 6.01 | 19.87 | 1,428,159 | 4.65 | 73.23% |
1 Year | 5.83 | 30.99 | 5.67 | 16.88 | 984,420 | 5.17 | 88.68% |
3 Years | 9.88 | 30.99 | 2.19 | 14.01 | 554,486 | 1.12 | 11.34% |
5 Years | 1.59 | 30.99 | 0.3511 | 7.82 | 666,775 | 9.41 | 591.82% |
EyePoint Pharmaceuticals Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. |